Trial Profile
A Phase 1/2 Trial of MG1 Maraba Expressing MAGE-A3 (MG1-MAGEA3), With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Pembrolizumab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs MG1 MA3 (Primary) ; MG1 MA3 (Primary) ; Pembrolizumab
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Sandpiper
- Sponsors Turnstone Biologics
- 05 Oct 2020 Status changed from active, no longer recruiting to completed.
- 10 Apr 2019 Status changed from suspended to active, no longer recruiting.
- 08 Apr 2019 Status changed from recruiting to suspended due to 'Awaiting for additional IP supply'.